

- Dementia (*Cont.*):
 in thiamine deficiency, 2607
 transient global amnesia and, 2608
 treatment of, 175–176
 vascular, 170, 172, 173t, **2602**
- Dementia pugilistica. *See* Chronic traumatic encephalopathy
- Dementia with Lewy bodies
 AD and, 2606
 clinical features of, 166, 172, 173, 173t, 2606
 vs. Creutzfeldt-Jakob disease, 453e-4–5
 molecular basis of, 172t
 neuropathology of, 2606
 olfactory dysfunction in, 214–215
 vs. Parkinson's disease dementia, 2617
 prions in, 444e-8f
 treatment of, 2606
- Demethylation, of DNA, 102e-8
- Demographic Transition, 93e-1
- de Montagnana, Petrus, 2f
- Dendritic cells
 in asthma, 1672
 definition of, 372e-1
 functions of, 372e-5f, 372e-6, 372e-7t, 372e-14f
 hematopoietic differentiation of, 89e-3f, 372e-6, 372e-9f
 in HIV infection, 1238
 myeloid, 372e-6, 372e-7t
 neoplasms of, 135e-8–9
 plasmacytoid 1, 372e-6, 372e-7t
- Dengue fever
 climate change and, 151e-4, 151e-5f, 151e-6f, 151e-8, 151e-8f
 clinical features of, 129t, 362, 783, 1319
 diagnosis of, 1319
 epidemiology of, 134, 151e-4, 151e-5f, 151e-8, 151e-8f, 783, 1318–1319
 prevention of, 796
 in returned traveler, 802, 802t
 severe, 783, 1322
- Dengue viruses, 1306t
- Dennie-Morgan folds, 344
- Denosumab
 action of, 102e-5t, 102e-11, 2501
 adverse effects of, 2501
 for hypercalcemia, 2481
 indications for, 2501
 for metastatic bone disease, 119e-4
 for osteoporosis management/prevention, 2501, 2502f
 for Paget's disease of bone, 426e-4
 prophylactic, in prostate cancer, 586
- Dense deposit disease, 62e-4f, 1841. *See also* Membranoproliferative glomerulonephritis
- Dense-granules, 275, 741
- Dental care/procedures
 in medically complex patient, 241–242
 preventive, 236
 prophylactic antibiotics for, 242, 826–827, 826t
- Dental disease
 brain abscess and, 901
 calculus, 46e-4f, 46e-5f
 caries, 46e-4f, 236, 1097
 gingivitis. *See* Gingivitis
 involuntary weight loss in, 275
 lymphadenopathy in, 408
 periodontitis. *See* Periodontal disease (periodontitis)
 plaque, 46e-4f, 236, 1097
 root cavity, 46e-4f
- Dental pulp stem cells, 453t
- Dentatorubropallidolusian atrophy, 440t, 451e-2t, 2629
- Dentin, 236
- Dent's disease, 332e-7t, 332e-8, 2459
- Dentures, 46e-1f, 46e-2f, 242
- Denys-Drash syndrome, 2353
- Deoxycoformycin, 103e-10t, 103e-14, 135e-2
- Deoxycorticosterone (DOC), 2309f, 2313, 2319
- Deoxyhemoglobin, 632, 632f
- DEPDC5* gene mutations, 2545t
- Dependence
 alcohol. *See* Alcohol use disorder (alcoholism)
 substance. *See* Substance use disorders
- Dependency ratios, 93e-4–5
- Depilatory, 334
- Depression/depressive disorders, **2714**
 agitated, 2717
 assessment of, 63
 in cancer, 473, 524, 2714
 in cardiovascular disease, 1514, 2714
 chemosensory alterations in, 215
 in chronic disease, 2714
 clinical features of, 2714–2715, 2715t
 in diabetes mellitus, 2714
 diagnosis of, 2715t
 dizziness in, 151
 drug-related, 2714
 etiology of, 63, 2715
 headache and, 108
 in HIV infection, 2714
 in hypothyroidism, 2714
 insomnia in, 190
 involuntary weight loss in, 275
 major depression, 2715, 2715t, 2716f
 nausea and vomiting in, 259
 in neurologic disorders, 2714
 AD, 2602
 epilepsy, 2558
 MS, 2663, 2672
 PD, 2617
 pain and, 93
 pathophysiology of, 465e-3–4, 465e-4f, 2715
 persistent, 2715
 postpartum, 6e-5
 screening for, 29t
 sexual dysfunction in, 326, 330
 in terminally ill patient, 63–64
 treatment of, **2715**
 algorithm for, **2716f**
 antidepressants, 2710t, 2711t, 2716–2717
 in cerebral function disorders, 184
 St. John's wort, 14e-4
 supportive, 2715–2716
 in terminally ill patient, 63–64
 unipolar, 2715
 in war veterans, 471e-4–5, 471e-5t
 in women, 6e-5, 2715
- de Quervain's tenosynovitis, 2220–2221, 2220f, 2248
- de Quervain's (subacute) thyroiditis, 239, 2298–2299, 2298f, 2298t
- Dermacentor* spp. ticks, 1154, 1319, 2745. *See also* Tick-borne diseases
- Dermal papillae, 827f
- Dermatitis, **344**
 atopic. *See* Atopic dermatitis
 contact. *See* Contact dermatitis
 in malabsorption syndromes, 1945
 seborrheic. *See* Seborrheic dermatitis
 stasis. *See* Stasis dermatitis
- Dermatitis herpetiformis, **373**
 celiac disease and, 373, 1942
 clinical features of, **373**
 distribution of lesions, 76e-14f, 340, 343f, 370t
 papules/vesicles, 76e-14f, 370t
 vesicles/bullae, 361t
 diagnosis of, 373
 histology of, 370t, 373
 HLA gene association with, 373, 373e-8t
 immunopathology of, 370t, 373
 treatment of, 373
- Dermatofibroma, 341t, 342f
- Dermatofibrosarcoma protuberans, 119e-2
- Dermatofibrosis lenticularis disseminata (Buschke-Ollendorff syndrome), 426e-5
- Dermatographism. *See* Dermographism
- Dermatoheliosis, 387
- Dermatomes, 160f, 161f
- Dermatomes, 160f, 161f
- Dermatomyositis, **2194**
 clinical features of, 157, 374, 2194–2196, 2195t
 calcinosis, 2202
 cutaneous, 374–375
 on face, 374f
 on hands, 76e-14f, 374f
 rash, 76e-13f
 telangiectasias, 356t, 357
 myocarditis, 1562
 Raynaud's phenomenon, 1649
 diagnosis of, 375, 2199–2200, 2199t, 2200f
 differential diagnosis of, 2197–2199
 immunopathogenesis of, 372e-24t, 2196, 2197f
 interstitial lung disease in, 1714
 malignancies associated with, 2196
 prognosis of, 2202
 treatment of, 2200–2202
- Dermatomyositis sine myositis, 374, 2195
- Dermatophagoides farinae*, 2121
- Dermatophagoides pteronyssinus*, 1669, 1671, 2121
- Dermatophytosis, **349**
 clinical features of, **349**
 distribution of lesions, 341t
 papulosquamous lesions, 347t, 350t
 diagnosis of, 350, 1357
 epidemiology of, 1357
 etiology of, 349, 350t, 1357
 histologic features of, 347t
 pathogenesis of, 1357
 treatment of, 350, 350t, 1357–1358, 1358t
- Dermographism, 76e-4f, 363, 363t, 2118, 2118f
- Dermoid cysts, 594, 603
- Dermopathy, thyroid, 2295, 2295f, 2297–2298
- DES (diethylstilbestrol), 103e-15, 477t, 585
- Descending perineum syndrome, 273
- Desensitization, 384
- Desipramine
 adverse effects of, 2710t, 2716
 for depression, 473, 2672, 2710t, 2716
 for irritable bowel syndrome, 1969
 for neuropathic pain, 94
 for pain, 91t, 93, 2672
 therapeutic monitoring of, 2764t
- Desmin
 in autoimmune disorders, 372e-24t
 functions of, 1553–1554
 mutations in, 1554
- Desmogleins, 371, 372e-24t, 373e-7, 377e-4
- Desmoplakin, 372e-25t
- Desmopressin (DDAVP)
 for adult hypopituitarism, 2259t
 adverse effects of, 731
 for central diabetes insipidus, 304
 for coagulation disorders in chronic kidney disease, 1818
 for diabetes insipidus, 2278–2279, 2279f
 for gestational diabetes insipidus, 303
 for hemophilia, 734
 for hypernatremia, 304
 for hypodipsic hypernatremia, 2280
 for hyponatremia, 64e-6–7, 303
 for nephrogenic diabetes insipidus, 64e-3, 304
 for orthostatic hypotension, 146
 for platelet function disorders, 730
 for sleep enuresis, 192
 structure of, 2275f
 for von Willebrand disease, 731
- Desmosome complexes, 1555t, 1556f, 1564
- Desmoteplase, 759, 759f
- Desquamative interstitial pneumonia, 1713
- Desvenlafaxine, 2710t
- Des- γ -carboxy prothrombin (DCP), 546, 547
- Detergent worker's lung, 1681t
- Detumescence, 325, 325f
- Developing world. *See* Low- and middle-income countries
- Device-related infections. *See* Health care-associated infections
- Devic's disease (neuromyelitis optica), 2656, 2673, 2673t
- DEXA (dual-energy x-ray absorptiometry), 2067, 2472, 2493
- Dexamethasone
 action of, 936
 adverse effects of, 462e-19
 for altitude illness, 476e-2–3, 476e-2t, 476e-4
 for brain abscess, 902